TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study

Autor: Mark A. Catherwood, Dorte Wren, Laura Chiecchio, Doriane Cavalieri, David Donaldson, Sarah Lawless, Ezzat ElHassadi, Amjad Hayat, Mary R. Cahill, Derville O’Shea, Jeremy Sargent, Peter Stewart, Manisha Maurya, John Quinn, Philip Murphy, David Gonzalez de Castro, Ken Mills, Nicholas C. P. Cross, Francesco Forconi, Sunil Iyengar, Anna Schuh, Patrick Thornton

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

Limited data exists to show the correlation of (tumour protein 53) TP53 mutation detected by Next generation sequencing (NGS) and the presence/absence of deletions of 17p13 detected by FISH. The study which is the largest series to date includes 2332

Externí odkaz: https://doaj.org/article/f68447793d1e43bead15fecab502e322

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Bortezomib before and after high-dose therapy in myeloma

Autor: Marian Stevens-Kroef, M. van Marwijk Kooy, Henk M. Lokhorst, Hans-Walter Lindemann, Anna Potamianou, Gerard M. J. Bos, B. van der Holt, Igor Wolfgang Blau, Annemiek Broijl, Christoph Scheid, Peter Brossart, Pieter Sonneveld, Sonja Zweegman, R. Schaafsma, Sandra Croockewit, Reinier Raymakers, Le Jarari, Ulrich Duehrsen, H Salwender, Jens Hillengass, Dirk Hose, Elias K. Mai, Anna Jauch, Marc-Steffen Raab, Michael Pfreundschuh, Thomas Hielscher, Paula F. Ypma, Marie-Jose Kersten, Katja Weisel, Edo Vellenga, H. Goldschmidt, Uta Bertsch

Publikováno v: Leukemia, 32(2), 383-390. Nature Publishing Group
Leukemia, 32, 2, pp. 383-390
Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, L, Salwender, H J & Sonneveld, P 2018, ' Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial ', Leukemia, vol. 32, no. 2, pp. 383-390 . https://doi.org/10.1038/leu.2017.211
Leukemia, 32(2), 383. Nature Publishing Group
Leukemia, 32, 383-390

The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell trans

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdac844a1794c65e65c209524742ae10
https://hdl.handle.net/11370/8335fc73-d259-436f-8a52-be9bb4049f03

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

Autor: Allyson Price, Alessandra Ferrajoli, Maria Tariq Siddiqui, Gautam Borthakur

Publikováno v: Leukemia Research Reports, Vol 16, Iss, Pp 100266-(2021)
Leukemia Research Reports

B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remiss

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a4eefbda2f1cc11026e28ee3254d10
https://doi.org/10.1016/j.lrr.2021.100266